Project Grant R15CA267804
Award Date
9/22/22
Completion Date
8/31/25
Dollars Obligated
$900K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Glendale, AZ 85308, USA
Similar Awards
This $391,250 Project Grant award from the National Institute of General Medical Sciences (CFDA 93.859 Biomedical Research and Research Training) will support research by The Regents of the University of Colorado (CU) to uncover the mechanistic basis for the recruitment and activation of the chromatin modifier enzymes Polycomb Repressive Complex 1 (PRC1), Polycomb Repressive Complex 2 (PRC2), and DNA Methyltransferase 1 (DNMT1). The research aims to provide novel structural and mechanistic...
This $449,726 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development of innovative tools to enable the rapid, sensitive analysis of dynamic changes in protein interactions within cells. The University of Illinois, the grant recipient, will create three new biotinylation methods that can label proteins in living cells within one minute or less, significantly improving the temporal resolution and signal-to-noise ratio over existing...
The federal Project Grant award R01CA293188, "Discovery of Small Molecules Targeting Polycomb Repressive Complexes 1 and 2," is funded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The $563,663 grant supports innovative research to identify small molecule inhibitors of Polycomb Repressive Complex 1 (PRC1) and PRC2, chromatin regulators that mediate transcriptional silencing and are implicated in various cancers. The research,...
This $1,104,864 Project Grant awarded by the National Cancer Institute (CFDA 93.396 Cancer Biology Research) supports research at the University of California, Davis to understand the molecular mechanisms of homologous recombination (HR) and how defects in recombinational DNA repair can lead to chromosomal instability and cancer predisposition. The key objectives are to elucidate the functions of BRCA2 protein and the RAD51 paralogs in mediating and potentiating homologous DNA pairing by...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $667,379 to the University of California, Irvine to conduct research aimed at decoding the role of polyadenylation in health and disease. The research will apply massively parallel reporter assays and machine learning to understand how polyadenylation site sequences determine mRNA processing efficiency and drug sensitivity. The findings will facilitate the discovery of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $530,697 to The Trustees of the University of Pennsylvania to conduct research on using protein arginine methyltransferase (PRMT) inhibitors to treat high-grade serous ovarian cancer and triple-negative breast cancer. The research aims to characterize the molecular mechanisms of PRMT inhibitor mono- and combination therapies, evaluate their therapeutic potential in preclinical...
This $898,660 project grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research into the role of SWI/SNF chromatin remodelers in homologous recombination and genome stability. The grant is awarded under the Cancer Cause and Prevention Research program (CFDA 93.393), which supports identification of cancer risks and mechanisms for prevention. The Midwestern University project will further define the mechanisms by which BRG1 and BRM stimulate...
The National Cancer Institute awarded a $138,489 Project Grant (CFDA 93.398 - Cancer Research Manpower) to the University of California, Irvine to develop a novel "methyl arginine targeting chimera" that can induce the lysosomal degradation of intracellular proteins. The research aims to characterize the mechanisms for applying this alternative protein degradation pathway, which is independent of the ubiquitin-proteasome system, and identify endogenous substrates that may be amenable...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) supports the development of a novel spatial proteomics approach to analyze immune cell populations and their functions within the tumor microenvironment. The $424,734 award to the University of Illinois will integrate 3D microscopy and proteomic techniques to provide in-depth, spatially-resolved profiles of immune cells across different regions of mouse tumor samples. This innovative method aims...
The National Cancer Institute (NCI) awarded a 5-year, $2,186,372 Project Grant under the CFDA 93.396 Cancer Biology Research program to the University of California, Irvine (UC Irvine). The grant will fund a multi-project program to address fundamental questions about the processes driving cancer initiation and progression. Three interdisciplinary research projects will leverage mouse models of chronic myeloid leukemia, melanoma, and BRCA1-driven triple-negative breast cancer to investigate...